LSM3, NDUFB3, and PTGS2 may be potential biomarkers for BRCA1-mutation positive breast cancer
By: Kang Hu, Fengjiao Gan, Xue Wang, Lin Xu, Qiaoyuan Wu, Ni Jiang and Suhong Sun
References
- 1. Güzey S, Aykan A, Avşar S, Yavan İ, Öztürk S. Recurrent Breast Cancer with Cutaneous Metastasis in the Late Term. Turkish Journal of Plastic Surgery. 2017;25(1):34+. DOI: 10.5152/TurkJPlast-Surg.2016.1980
- 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Ca Cancer J Clin. 2017;67(1):7-30. DOI: 10.3322/caac.2138710.3322/caac.21387
- 3. Cancer UK. Breast cancer symptoms. 2010.
- 4. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition: An International Review Journal. 2016;7(2):418-9. DOI: 10.3945/an.116.01221110.3945/an.116.012211
- 5. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. Ca Cancer J Clin. 2016;66(2):115-32. DOI: 10.3322/caac.2133810.3322/caac.21338
- 6. Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Onco-target. 2017;8(18):30576-86. DOI: 10.18632/oncotarget.1573610.18632/oncotarget.15736
- 7. Robson ME, Chappuis PO, Jaya S, Nora W, Jeff B, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2003;6(1):R8. DOI: 10.1186/bcr65810.1186/bcr658
- 8. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama. 2017 Jun 20;317(23):2402-16.
- 9. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36(10):1200-8. DOI: 10.1016/S0959-8049(00)00110-610.1016/S0959-8049(00)00110-6
- 10. Liu X, Ma Y, Yang W, Wu X, Jiang L, Chen X. Identification of therapeutic targets for breast cancer using biological informatics methods. Mol Med Rep. 2015;12(2):1789. DOI: 10.3892/mmr.2015.356510.3892/mmr.2015.3565446409025824986
- 11. Zhao Y, Bing F. Screening of biomarkers for prediction of response to and prognosis after chemotherapy for breast cancers. Onco Targets Ther. 2016;9(Issue 1):2593-600. DOI: 10.2147/OTT.S9235010.2147/OTT.S92350486100127217777
- 12. Wu D, Han B, Guo L, Fan Z. Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis. J Obstetrics & Gynaecology. 2016;36(5):615-21. DOI: 10.3109/01443615.2015.112790210.3109/01443615.2015.112790226804550
- 13. Athar A, Fullgrabe A, George N, Iqbal H, Huerta L, Ali A, et al. ArrayExpress update - from bulk to single-cell expression data. Nucleic acids res. 2019 Jan 8;47(D1):D711-d5. DOI: 10.1093/nar/gky96410.1093/nar/gky964632392930357387
- 14. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363-7. DOI: 10.1093/bioinformatics/btq43110.1093/bioinformatics/btq431294419620688976
- 15. Smyth GK. limma: Linear Models for Microarray Data. Bioinformatics & Computational Biology Solutions Using R & Bioconductor. 2011:397-420. DOI: 10.1007/0-387-29362-0_2310.1007/0-387-29362-0_23
- 16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. DOI: 10.1073/pnas.050658010210.1073/pnas.0506580102123989616199517
- 17. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000 Jan 1;28(1):27-30. DOI: 10.1093/nar/28.1.2710.1093/nar/28.1.2710240910592173
- 18. Shannon, P. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003;13(11):2498. DOI: 10.1101/gr.123930310.1101/gr.123930340376914597658
- 19. Therneau TM, Grambsch PM, Modeling Survival Data: Extending The Cox Model. 2000. DOI: 10.1007/978-1-4757-3294-810.1007/978-1-4757-3294-8
- 20. Fromont-Racine M, Rain JC, Legrain P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet. 1997 Jul;16(3):277-82. DOI: 10.1038/ng0797-27710.1038/ng0797-2779207794
- 21. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, et al. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget. 2017;8(2):2423-36. DOI: 10.18632/oncotarget.1368210.18632/oncotarget.13682535681227911856
- 22. Xie N, Yao Y, Wan L, Zhu T, Liu L, Yuan J. Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Exp Ther Med. 2017;14(1):338-43. DOI: 10.3892/etm.2017.446410.3892/etm.2017.4464548863128672935
- 23. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482-90. DOI: 10.1158/1078-0432.CCR-17-307010.1158/1078-0432.CCR-17-307029420223
- 24. Sotgia F, Lisanti MP. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget. 2017;8(40):68095-107. DOI: 10.18632/onco-target.19677
- 25. Liu X-H, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin exp metastasis. 1999;17(8):687-94. DOI: 10.1023/A:100672811954910.1023/A:1006728119549
- 26. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31(3):455-61. DOI: 10.1093/carcin/bgp30710.1093/carcin/bgp307
- 27. Festa-Vasconcellos JS, Piranda DN, Amaral LM, Indio-do-Brasil V, Koifman S, Vianna-Jorge R. Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features. Breast cancer res treat. 2012;132(1):251-8. DOI: 10.1007/s10549-011-1828-010.1007/s10549-011-1828-0
- 28. De CP, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, et al. COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. Anticancer Res. 2018;38(3):1485. DOI: 10.21873/anticanres.1237510.21873/anticanres.12375
- 29. Goswami BB, Michael K, Diana N, Cebula TA. Apoptosis induced by a cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA degradation but occurs in the absence of 2’-5’ oligoadenylate synthetase. Antiviral Res. 2004;63(3):153-66. DOI: 10.1016/j.antiviral.2004.02.00410.1016/j.antiviral.2004.02.004
- 30. Kocic G, Jevtovic T, Pavlovic D, Bjelakovic G, Kocic R. 290 A role of IFN-α in the double-stranded RNA degradation during Fas-ligand induced liver apoptosis and balance between proliferation and death. J Hepatol. 2006;44(06):S113-S. DOI: 10.1016/S0168-8278(06)80291-610.1016/S0168-8278(06)80291-6
- 31. Koedoot E, Dévédec SL, Water BVD. Abstract 893: Systematic assessment of spliceosome components as drivers of breast cancer progression. Cancer Res. 2017;77(13 Supplement):893. DOI: 10.1158/1538-7445.AM2017-89310.1158/1538-7445.AM2017-893
- 32. Quidville V, Alsafadi S, Goubar A, Commo F, Scott V, Pioche-Durieu C, et al. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 2013;73(7):2247-58. DOI: 10.1158/0008-5472.CAN-12-250110.1158/0008-5472.CAN-12-250123358685
- 33. Soto-Guzman A, Villegas-Comonfort S, Cortes-Reynosa P, Salazar EP. Role of arachidonic acid metabolism in Stat5 activation induced by oleic acid in MDA-MB-231 breast cancer cells. Prostaglandins Leukotrienes & Essential Fatty Acids. 2013;88(3):243-9. DOI: 10.1016/j. plefa.2012.12.003
- 34. Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. Plos One. 2013;8(7):e68566. DOI: 10.1371/journal.pone.006856610.1371/journal.pone.0068566370261423861918
- 35. Chun-Te C, Yi D, Hirohito Y, Jung-Mao H, Hsu-Ping K, Hortobagyi GN, et al. Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012;11(10):2212-21. DOI: 10.1158/1535-7163. MCT-12-0180
Language: English
Page range: 381 - 391
Submitted on: Jul 23, 2020
Accepted on: Oct 28, 2020
Published on: Nov 18, 2020
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2020 Kang Hu, Fengjiao Gan, Xue Wang, Lin Xu, Qiaoyuan Wu, Ni Jiang, Suhong Sun, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.